How Reliable Is a Gleason Score? What It Reveals and What It Misses

Stephen Petteruti, DO
Board-Certified Family Physician
Founder and Medical Director, Intellectual Medicine
Medical Review Date: July 31, 2026

A man undergoes a prostate biopsy and, within days, receives a numerical result that may significantly influence his future medical decisions.

Gleason 6. Gleason 7. Gleason 8.

As the Gleason score increases, the seriousness of the clinical discussion intensifies. Treatment options such as surgery, radiation, and hormone suppression are often considered before the patient fully understands the implications and limitations of the score.

The Gleason score provides useful information about how prostate tissue looks under a microscope. It also has meaningful limitations. It is based on a small tissue sample, depends partly on a pathologist’s interpretation, and captures one moment in time.

A Gleason score possesses established prognostic value. However, it does not definitively predict disease behavior, potential for metastasis, or which treatment will best balance longevity and quality of life.

Before making a significant prostate cancer treatment decision, it is essential to understand both the strengths and limitations of the Gleason score.

What Is a Gleason Score?

The Gleason score is a prostate cancer grading system based on the microscopic appearance of prostate tissue.

A pathologist examines tissue obtained during a prostate biopsy or surgery. The pathologist identifies the two most common growth patterns and assigns each a grade. These two grades are added together.

For example:

• Gleason 3 + 3 = 6
• Gleason 3 + 4 = 7
• Gleason 4 + 3 = 7
• Gleason 4 + 4 = 8
• Gleason 4 + 5 = 9

The first number represents the dominant pattern. This is why a Gleason 3 + 4 is not the same as a Gleason 4 + 3, even though both add up to seven. The 4 + 3 sample contains more pattern 4 tissue and is associated with a less favorable prognosis.

Contemporary pathology also uses Grade Groups:

• Grade Group 1: Gleason 3 + 3 = 6
• Grade Group 2: Gleason 3 + 4 = 7
• Grade Group 3: Gleason 4 + 3 = 7
• Grade Group 4: Gleason score 8
• Grade Group 5: Gleason scores 9 or 10

The Grade Group system helps clarify differences hidden by the older Gleason totals. It also avoids the confusing impression that a Gleason 6 represents a score in the middle of a ten-point scale. Under the current system, Grade Group 1 is the lowest grade assigned to prostate cancer.

The International Society of Urological Pathology has continued to update prostate cancer grading standards as researchers identify additional features linked with prognosis.

What Does a Gleason Score Tell You?

A Gleason score describes the architectural pattern of the cancer cells found in the tissue sample. Higher-grade patterns tend to be associated with a greater risk of progression, recurrence, and metastasis.

This makes the score clinically useful.

Challenges arise when the Gleason score is interpreted as providing information beyond its actual scope.

A Gleason score does not independently tell you:

• How quickly the cancer is changing
• Whether it is currently spreading
• How much cancer exists throughout the prostate
• Whether the biopsy sampled the highest-grade area
• How your PSA has behaved over time
• Whether the disease is contained within the prostate
• Whether immediate treatment will improve your survival
• Which treatment best fits your age, health, priorities, and risk tolerance

While grade is important, it must be interpreted alongside PSA history, imaging results, clinical stage, prostate and cancer volume, pathology details, patient age, health status, and longitudinal changes.

Why Gleason Scores Differ Between Pathologists

Gleason grading involves expert visual interpretation. It is not produced by a machine reading an objective numerical measurement.

Pathologists receive extensive training, and contemporary grading standards have improved consistency. Even so, disagreement still occurs.

A nationwide study of 35,258 men in the Netherlands found meaningful variation in Gleason grading between pathology laboratories and among pathologists working within the same laboratory. The researchers concluded that grading variation found in controlled studies also exists in routine clinical practice.

A separate blinded study involving 407 prostate biopsy slides found concordance rates of approximately 64% for primary and secondary Gleason patterns between two pathologists. The pathologists also disagreed about the presence of a tumor in some samples.

Another multicenter study asked eight pathologists from six institutions to review the same slides. It found continued interobserver variation, including differences between general pathologists and specialists in urologic pathology.

These findings do not indicate that every Gleason score is inaccurate; rather, they demonstrate that the score incorporates a degree of human interpretation.

When a treatment decision could affect urinary control, sexual function, energy, and quality of life, obtaining a second pathology review from an experienced genitourinary pathologist deserves consideration.

A Biopsy Samples Only Part of the Prostate

The prostate is not uniform. Different areas of the same gland could contain different cellular patterns.

A needle biopsy collects small cores from selected locations. Even with MRI targeting, the procedure does not examine every part of the prostate.

One core might contain pattern 3 tissue while another contains pattern 4. A higher-grade area could be missed. A small focus of higher-grade tissue could also receive more weight than its overall volume might suggest.

This creates two possible problems.

Undergrading

The biopsy misses a higher-grade area, and the reported score is lower than the grade found later in the prostatectomy specimen.

Upgrading or Reclassification

A later biopsy or surgical specimen identifies a different grade because it sampled more tissue or a different part of the gland.

When a later score changes, it does not always mean the cancer transformed during the interval. The difference could reflect sampling or interpretation.

This underscores the importance of viewing a biopsy result as information derived from sampled tissue, rather than as a comprehensive representation of the entire prostate.

Why One Gleason Score Cannot Show Change Over Time

A Gleason score is a snapshot. It describes the tissue collected on one date.

It does not provide a trend.

Prostate cancer risk unfolds over time. A man’s clinical picture could remain stable for years, or his markers and imaging could begin changing within a shorter period.

Sequential assessment helps identify the difference.

I look at:

• PSA direction and rate of change
• Repeated PSA results obtained under consistent conditions
• Prostate volume and PSA density
• Prostate Health Index or other biomarkers when appropriate
• MRI findings and changes between studies
• Symptoms
• Evidence of extension outside the prostate
• The man’s age, metabolic health, hormonal status, and overall health

A PSA that rises once and then returns to its prior range creates a different picture from a PSA that continues rising across several scheduled tests.

PSA testing also has limitations. Factors such as benign prostatic enlargement, inflammation, infection, ejaculation, physical activity, instrumentation, medications, and hormonal fluctuations can influence results. Therefore, a single PSA measurement should not solely determine clinical decisions.

The value comes from looking at multiple pieces of information together and following them over time.

The Anxiety Created by a Gleason Score

The word cancer changes the emotional temperature of the room. A high Gleason score increases it again.

Men often feel that they must act immediately. They hear words such as “aggressive” and begin thinking that every day without treatment gives the cancer more time to spread.

Prostate cancer often does not operate on that timetable.

Some prostate cancers require prompt intervention. Others remain localized or progress slowly. The challenge is separating those situations without allowing fear to make the decision.

Alleviating patient anxiety does not necessarily equate to improved clinical outcomes.

Surgery might remove the prostate and lower PSA, but it also carries possible consequences involving urinary continence, sexual function, and other aspects of daily life. Radiation has its own short-term and long-term effects. Hormone suppression affects muscle, bone, metabolism, sexual function, energy, and emotional health.

A man should understand what benefit a treatment is expected to provide and what function he risks losing.

The Gleason score should be included in the decision-making process, but it must not be the sole determinant.

What the ProtecT Trial Teaches Us About Treatment Decisions

The ProtecT trial followed 1,643 men with localized prostate cancer who were assigned to active monitoring, prostatectomy, or radiotherapy.

After a median of 15 years, prostate cancer-specific mortality remained low in all three groups. Death from prostate cancer occurred in 3.1% of the active-monitoring group, 2.2% of the prostatectomy group, and 2.9% of the radiotherapy group. The differences were not statistically significant.

That finding supports a measured decision process for many men with localized prostate cancer. It does not mean that treatment never has value.

Metastases occurred more often in the active-monitoring group: 9.4% compared with 4.7% after prostatectomy and 5.0% after radiotherapy. Clinical progression and the use of long-term androgen-deprivation therapy were also higher with monitoring.

There is another limitation. The active-monitoring protocol began more than two decades ago and relied heavily on PSA. It does not reflect every component of modern risk assessment, MRI use, or contemporary surveillance.

The correct lesson is not that surgery, radiation, and monitoring produce identical outcomes in every respect. The lesson is that prostate cancer-specific death remained uncommon across all three groups, while progression, treatment complications, and quality-of-life effects differed.

Treatment decisions require a careful discussion of those trade-offs, not a reflexive response to one number. The full 15-year ProtecT trial results were published in The New England Journal of Medicine.

The Risks of Obtaining a Gleason Score

A Gleason score requires prostate tissue. In most cases, this means undergoing a biopsy.

Prostate biopsy risks include:

• Blood in the urine, semen, or stool
• Pain or discomfort
• Difficulty urinating
• Urinary retention
• Infection
• Hospitalization
• Sepsis

Transperineal biopsy has reduced the risk of infection compared with the traditional transrectal approach, but no invasive procedure is free of risk.

A large real-world study of transrectal biopsy procedures documented both infectious and noninfectious complications, including bleeding, urinary retention, pain, and sepsis among patients who experienced an infection.

The statistics from this study must be interpreted correctly. For example, percentages for urinary retention and bleeding were reported among the patients with documented complications, not among every man who underwent a biopsy. They should not be presented as though one-third of all biopsy patients experienced those outcomes.

The broader consideration is that biopsy procedures carry inherent risks. Before proceeding, patients should inquire how the results will influence their clinical management.

Questions to Ask Before Acting on a Gleason Score

If you have received a Gleason score, slow the process down enough to understand what it means.

Ask:

Was the pathology reviewed by a genitourinary pathologist?

A specialist review might confirm the grade or identify a meaningful difference.

What is the Grade Group?

Grade Groups make the distinction between Gleason 3 + 4 and 4 + 3 clearer.

How much pattern 4 or pattern 5 was present?

The amount and type of higher-grade tissue influence risk. Ask whether cribriform architecture or intraductal carcinoma was identified, since these features have separate prognostic significance.

How many cores contained cancer?

The number of positive cores and the amount of cancer in each core provide context beyond the total Gleason score.

Does the MRI agree with the pathology?

Imaging could help assess lesion location, size, prostate volume, and possible extension. MRI has limitations and does not provide a microscopic grade, but agreement or disagreement between findings matters.

What has the PSA done over time?

A trend across several tests provides more information than one isolated PSA.

Is the cancer believed to be contained?

Clinical stage and imaging findings affect the risk discussion.

What outcome is the proposed treatment expected to improve?

Ask about prostate cancer mortality, metastasis, progression, urinary function, sexual function, bowel effects, and the possible need for future treatment.

What happens if the decision is delayed while more information is gathered?

Not every diagnosis necessitates immediate intervention. The appropriate course of action depends on a comprehensive assessment of the individual’s risk profile.

A More Complete Approach to Prostate Cancer Risk

I do not believe men should make life-changing decisions from a Gleason score alone.

A more complete assessment looks at the disease from several directions:

Sequential PSA Testing

Repeat testing helps separate a persistent trend from a temporary fluctuation. Testing conditions should remain as consistent as possible.

Prostate Volume and PSA Density

A larger prostate often produces more PSA. PSA density places the PSA result in the context of prostate size.

Prostate MRI

MRI provides information about the gland, suspicious lesions, and possible extension. It also establishes a baseline for comparison with later imaging.

Additional Biomarkers

Depending on the situation, the Prostate Health Index, 4Kscore, urine-based tests, or other tools could add information. Each has limits, costs, and a specific intended use.

Expert Pathology Review

If biopsy tissue already exists, a second review is less invasive than repeating the biopsy and could clarify the Grade Group or tissue pattern.

Clinical Context

Age, other health conditions, family history, genetic risk, symptoms, personal priorities, and expected longevity belong in the decision.

No single diagnostic test provides all necessary information. The objective is to construct a coherent and comprehensive clinical assessment.

My View on the Gleason Score

The Gleason system has contributed to prostate cancer classification for decades. It helps distinguish lower-grade tissue from patterns associated with greater risk.

I acknowledge the value of the Gleason score, but I do not support relying on it as the sole basis for treatment decisions.

The score is based on selected tissue, subject to sampling limitations and interpretive variation. It does not measure change over time. It does not determine whether immediate treatment will improve an individual man’s survival. It does not account for the effect of treatment on the rest of his life.

An individual’s identity and prognosis extend beyond the findings of a pathology report.

If you already have a Gleason score, use it as one part of the assessment. Confirm the pathology when appropriate. Review the Grade Group and higher-risk tissue patterns. Examine the PSA trend. Compare the findings with imaging. Ask what each proposed intervention is expected to accomplish.

Permanent treatment decisions should not be made based on incomplete information or emotional responses.

The Bottom Line

A Gleason score provides useful information about the appearance of prostate cancer cells. Higher Grade Groups are associated with greater clinical risk, but the score has limitations.

Pathologists sometimes disagree. A biopsy samples only part of the prostate. One result does not show how the condition is changing. The score also cannot determine by itself whether surgery, radiation, monitoring, or another approach offers the right balance of benefit and harm for one man.

Before choosing treatment, examine the full picture.

Track changes. Confirm findings. Understand the limitations of each test. Ask how the proposed treatment affects survival, progression, urinary control, sexual function, and quality of life.

Patients are encouraged to take the necessary time to seek comprehensive information and ask informed questions.

Frequently Asked Questions Regarding Gleason Scores

Is a Gleason score accurate?

A Gleason score offers significant prognostic information, although it is not entirely reproducible. Results may vary due to differences in biopsy sampling and interpretation among pathologists. When results will influence major treatment decisions, review by a genitourinary pathologist is recommended.

Could a Gleason score change after a second review?

Yes. A second pathologist may assign a different pattern or Grade Group to the same tissue sample. Additionally, a subsequent biopsy or prostatectomy specimen may yield a different grade if it includes more tissue or samples a different region.

Is Gleason 6 considered aggressive prostate cancer?

Gleason 3 + 3, also known as Grade Group 1, represents the lowest current prostate cancer grade and is generally associated with a lower risk profile. However, its clinical significance depends on factors such as cancer volume, PSA history, imaging findings, clinical stage, and overall patient health.

What is the difference between Gleason 3 + 4 and 4 + 3?

Although both scores total seven, they are not equivalent. Gleason 3 + 4 indicates a predominance of pattern 3 tissue and corresponds to Grade Group 2. In contrast, Gleason 4 + 3 reflects a higher proportion of pattern 4 tissue and is classified as Grade Group 3, which is associated with a less favorable prognosis.

Does a high Gleason score mean treatment must begin immediately?

A higher Grade Group requires thorough evaluation. The timing and selection of treatment depend on the comprehensive clinical context, including disease stage, imaging results, PSA trends, symptoms, patient age, overall health, and evidence of metastasis.

Does MRI replace a Gleason score?

MRI and pathology provide distinct types of information. MRI visualizes the prostate’s anatomy and identifies suspicious regions, but does not offer microscopic grading. Each modality has limitations and should be interpreted in conjunction with the complete clinical context.

About Dr. Stephen Petteruti

Stephen Petteruti, DO, is a board-certified family physician with more than 35 years of clinical experience. He is the founder and medical director of Intellectual Medicine, where his work focuses on men’s health, hormone and metabolic health, preventive medicine, and long-term prostate cancer risk assessment.

Dr. Petteruti works directly with men navigating elevated PSA results, prostate imaging, biopsy recommendations, Gleason scores, and prostate cancer treatment decisions. As a family physician rather than a surgeon, he approaches these decisions through a whole-patient lens, examining long-term health, treatment risks, sexual and urinary function, metabolic health, and quality of life.

He is the author of Fight Cancer Like a Man: A Breakthrough Treatment for Prostate Cancer Without Surgery, Radiation, or Sacrificing Your Manhood and host of the Intellectual Medicine Podcast. His work combines decades of clinical experience with peer-reviewed research and longitudinal patient monitoring.

References

1. Flach RN, Willemse PM, Suelmann BBM, et al. Significant inter- and intralaboratory variation in Gleason grading of prostate cancer: a nationwide study of 35,258 patients in the Netherlands. Cancers. 2021;13(21):5375.
2. Ozkan TA, Eruyar AT, Cebeci OO, Memik O, Ozcan L, Kuskonmaz I. Interobserver variability in Gleason histological grading of prostate cancer. Scandinavian Journal of Urology. 2016;50(6):420-424.
3. Dere Y, Altun E, Yıldız HT, et al. A grading dilemma: Gleason scoring system. International Journal of Clinical and Experimental Pathology. 2020;13(2):236-249.
4. Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England Journal of Medicine. 2023;388(17):1547-1558.
5. Sosenko A, Owens K, Timoney AG, Hinchliffe A. Non-infectious complications following transrectal prostate needle biopsy. Prostate International. 2022;10(3):157-162.
6. van Leenders GJLH, van der Kwast TH, Grignon DJ, et al. The 2019 International Society of Urological Pathology consensus conference on grading of prostatic carcinoma. American Journal of Surgical Pathology. 2020;44(8):e87-e99.